CNBC interview (link):
- Forayed into diagnostics, want to position itself as a complete healthcare organization. This is being done in a calibrated way
- Conscious of expensive M&A (once bitten twice shy)
- Seeing pricing pressure in US (high single digit). Expect it to settle down at 5-6%
- Suprep: expect launch in H2FY23
- Goa observations: Addressable and no repeat, confident of addressing them
- Somerset: Three observations are common with the warning letter. No timeline given toward its settlement
- Tarapur & Pithampur: Ready for reinspection. No important products are coming from there
- A lot of KSMs are sourced from China which are showing price increases
- Looking to spin off its NCE molecules which offer good value, want to unleash value from biosimilar division
Disclosure: Invested (position size here)